tbuckley/cabot-search huggingface dataset:
Association of Sarcopenia and Body Composition With Short-term Outcomes After Liver Resection for Malignant Tumors
Authors: Giammauro Berardi, Giulio Antonelli, Marco Colasanti, Roberto Meniconi, Nicola Guglielmo, Andrea Laurenzi, Stefano Ferretti, Giovanni Battista Levi Sandri, Alessandra Spagnoli, Giovanni Moschetta, Vincenzo Schininà, Mario Antonini, Massimo Marignani, Giuseppe Maria Ettorre
Journal: JAMA Surgery (2020)

Previous retrospective studies have shown that sarcopenia substantially alters the postoperative and oncological outcomes after liver resection for malignant tumors. However, the evidence is limited to small retrospective studies with heterogeneous results and the lack of standardized measurements of sarcopenia.To investigate the role of sarcopenia as a risk factor associated with 90-day morbidity after liver resection for malignant tumors.This cohort study included 234 consecutive patients undergoing liver resection for malignant tumors at San Camillo Forlanini Hospital, Rome, Italy, between June 1, 2018, and December 15, 2019. Muscle mass and strength were assessed using the skeletal muscle index (SMI) on preoperative computed tomographic scans and the handgrip strength test, respectively. Patients were then divided into the following 4 groups: group A (normal muscle mass and strength), group B (reduced muscle strength), group C (reduced muscle mass), and group D (reduced muscle mass and strength).The primary outcome of the study was 90-day morbidity. The following secondary outcomes were investigated: 90-day mortality, hospital stay, and readmission rate.Sixty-four major and 170 minor hepatectomies were performed in 234 patients (median age, 66.50 [interquartile range, 58.00-74.25] years; 158 men [67.5%]). The median SMI of the entire population was 46.22 (interquartile range, 38.60-58.20) cm/m2. The median handgrip strength was 30.80 (interquartile range, 22.30-36.90) kg. Patients in group D had a statistically significantly higher rate of 90-day morbidity than patients in the other groups (51.5% [35 of 68] vs 38.7% [29 of 75] in group C, 23.1% [3 of 13] in group B, and 6.4% [5 of 78] in group A; P < .001). Compared with patients in the other groups, those in group D had a longer hospital stay (10 days vs 8 days in group C, 9 days in group B, and 6 days in group A; P < .001), and more patients in this group were readmitted to the hospital (8.8% [6 of 68] vs 5.3% [4 of 75] in group C, 7.7% [1 of 13] in group B, and 0% [0 of 78] in group A; P = .02). Sarcopenia, portal hypertension, liver cirrhosis, and biliary reconstruction were independent risk factors associated with 90-day morbidity.Sarcopenia appears to be associated with adverse outcomes after liver resection for malignant tumors. Both muscle mass measurements on computed tomographic scans and muscle strength assessments with the handgrip strength test should be performed at the first clinical encounter to better classify patients and to minimize the risk of morbidity.
535MO BGB-A333, an anti-PD-L1 monoclonal antibody, in combination with tislelizumab in patients with urothelial carcinoma
Authors: J. Martin Liberal, P.C. Fong, V. Moreno, S. Frentzas, J. Desai, T. Meniawy, B. Markman, M. Voskoboynik, N. Budha, J. Wu, W. Shen, M. Singh, E. Calvo
Journal: Annals of Oncology (2020)
Abstract PO-022: Impact of COVID-19 pandemic on new patient and consult visits at 20 hematology/oncology practices in the ASCO PracticeNET learning network
Authors: Brian Bourbeau, Mou Guharoy, Elizabeth Garrett-Mayer, Stephen Grubbs, Paul Unger, Barbara McAneny, Richard L. Schilsky
Journal: Clinical Cancer Research (2020)

Abstract Introduction: During March 2020, as the emergence of COVID-19 began to influence medical and social behaviors in the United States, oncology practices reported a disruption in normal referral and patient management patterns. Participants and staff of ASCO's PracticeNET learning network sought to explore and quantify the impact of this disruption through an analysis of patient activity at multiple hematology/oncology practices. Methods: 20 practices submitted their billing data for analysis; practices were located in 14 states and ranged in size from 2 to 29 hematologists/oncologists. From this dataset we analyzed a total of 11,453 new patient and consult visits (Current Procedural Terminology codes 99201-99205, 99241-99245, 99251-99255, and 99341-99345) performed by hematologists/oncologists from February 9 to April 18, 2020. The number of visits performed from February 9 to March 14, 2020 was compared to visits performed from March 15 to April 18, 2020. A principal diagnosis was assigned to each visit following usual coding and billing practices. Results: From February 9 to March 14, practices performed an average of 70.1 (median 55.5) new patient and consult visits per week. From March 15 to April 19, practices performed an average of 44.5 new patient and consult visits per week. The average decrease in visits among practices was 35% (95% confidence interval (CI): -42%, -29%). The decline in visits per practice ranged from -61% to -13%. New patient and consult visits for solid neoplasms decreased by an average of 22% (95% CI: -31%, -13%), visits for blood neoplasms decreased by an average of 36% (95% CI: -25%, -47%), and visits for benign hematology and circulatory disorders decreased by an average of 44% (95% CI: -53%, -34%). Conclusions: Oncology practices experienced a decline in new patient and consult visits, first observed in the week of March 15. New patient and consult visits for blood neoplasms, benign hematology, and circulatory disorders experienced a greater decline than visits for solid neoplasms. The decrease in activity could be the result of prioritization of resources or changes in patient behavior in seeking care. Further study is necessary to quantify the impact of these findings on patient access and outcomes and to monitor recovery efforts. Citation Format: Brian Bourbeau, Mou Guharoy, Elizabeth Garrett-Mayer, Stephen Grubbs, Paul Unger, Barbara McAneny, Richard L. Schilsky. Impact of COVID-19 pandemic on new patient and consult visits at 20 hematology/oncology practices in the ASCO PracticeNET learning network [abstract]. In: Proceedings of the AACR Virtual Meeting: COVID-19 and Cancer; 2020 Jul 20-22. Philadelphia (PA): AACR; Clin Cancer Res 2020;26(18_Suppl):Abstract nr PO-022.
708MO Metachronous contralateral testicular cancer in the cisplatin era: A population-based cohort study
Authors: R. Hellesnes, T.Å. Myklebust, Ø. Kvammen, R. Bremnes, Á. Karlsdottir, H.F.S. Negaard, T. Tandstad, T. Wilsgaard, S.D. Fosså, H.S. Sagstuen Haugnes
Journal: Annals of Oncology (2020)
965P Role of STAT3 (signal transducer and activator of transcription 3) activation and its regulation by PTPRT (protein receptor tyrosine phosphatase type T) and response to paclitaxel and cetuximab in patients (P) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)
Authors: B. Cirauqui Cirauqui, A. Bernat Peguera, A. Quer Pi-Sunyer, J.L. Ramírez Serrano, M. Domenech Viñolas, I. Teruel García, V. Quiroga García, M. Margeli Vila, I. Chaib, L. Capdevila Riera, A. Ferrando Diez, A. Plaja Salarich, L. Angelats Company, S. España Fernandez, G. Berenguer Peinado, C. Lezcano Rubio, C. Pollan Guisasola, A. Martinez Cardús, R. Rosell Costa, R. Mesia Nin
Journal: Annals of Oncology (2020)
Osteoporosis and fracture risk associated with inhaled corticosteroid use among Swedish COPD patients: the ARCTIC study
Authors: Christer Janson, Karin Lisspers, Björn Ställberg, Gunnar Johansson, Florian S. Gutzwiller, Karen Mezzi, Linda Mindeholm, Bine Kjoeller Bjerregaard, Leif Jorgensen, Kjell Larsson
Journal: European Respiratory Journal (2020)

The effect of inhaled corticosteroids (ICS) on the risk of osteoporosis and fracture in patients with chronic obstructive pulmonary disease (COPD) remains uncertain. The aim of this study was to assess this risk in patients with COPD. Electronic medical record data linked to National Health Registries were collected from COPD patients and matched reference controls at 52 Swedish primary care centres from 2000 to 2014. The outcomes analysed were the effect of ICS on all fractures, fractures typically related to osteoporosis, recorded osteoporosis diagnosis, prescriptions of drugs for osteoporosis and a combined measure of any osteoporosis-related event. The COPD patients were stratified by the level of ICS exposure. A total of 9651 patients with COPD and 59 454 matched reference controls were analysed. During the follow-up, 19.9% of COPD patients had at least one osteoporosis-related event compared with 12.9% of reference controls (p&lt;0.0001). Multivariate analysis in the COPD population demonstrated a dose–effect relationship, with high-dose ICS being significantly associated with any osteoporosis-related event (risk ratio 1.52 (95% CI 1.24–1.62)), while the corresponding estimate for low-dose ICS was 1.27 (95% CI 1.13–1.56) compared with COPD patients not using ICS. A similar dose-related adverse effect was found for all four of the specific osteoporosis-related events: all fractures, fractures typically related to osteoporosis, prescriptions of drugs for osteoporosis and diagnosis of osteoporosis. We conclude that patients with COPD have a greater risk of bone fractures and osteoporosis, and high-dose ICS use increased this risk further.
1168P Survey of challenges in access to diagnostics and treatment for neuroendocrine tumour (NET) patients (SCAN): Healthcare quality evaluation
Authors: C.V. Bouvier, D. Van Genechten, T. Kolarova, M. McDonnell, D. O'Toole, H. Singh, J. Chen, J. Howe, S. Singh, C. Rodien-Louw, S. Leyden, S. Dureja
Journal: Annals of Oncology (2020)
Intensive care unit acquired muscle weakness in COVID-19 patients
Authors: Nathalie Van Aerde, Greet Van den Berghe, Alexander Wilmer, Rik Gosselink, Greet Hermans, Philippe Meersseman, Jan Gunst, Vicky Aerts, Tim Balthazar, Astrid Barbé, Arne Böhrer, Kim Caluwé, Michael P. Casaer, Iris Coosemans, Steve Coppens, Dieter Dauwe, Yves Debaveye, Johan De Coster, Paul De Munter, Lot Demuynck, Veerle De Sloovere, Lars Desmet, Erwin De Troy, Greet De Vlieger, Bregje Frickx, Eline Haghedooren, Renata Haghedooren, Liesbet Henckaerts, Arne Heyns, Miek Hornikx, Catherine Ingels, Bart Jacobs, Kristel Janssen, Wouter Meersseman, Geert Meyfroidt, Jan Muller, Arne Neyrinck, Marijke Peetermans, Steffen Rex, An Schrijvers, Peter Vanbrabant, Christophe Vandenbriele, Raf Van den Eynde, Marleen van den Hauwe, Marc Van de Velde, Marine Van Hollebeke, Eric Van Wijngaerden, Sandra Verelst, Dirk Vlasselaers, Claudia Volker, Bart Vrijsen, Joost Wauters, Pieter J. Wouters
Journal: Intensive Care Medicine (2020)
First clinical study of a pegylated diabody <sup>124</sup>I-labeled PEG-AVP0458 in patients with tumor-associated glycoprotein 72 positive cancers
Authors: Andrew M. Scott, Timothy Akhurst, Fook-Thean Lee, Marika Ciprotti, Ian D. Davis, Andrew J. Weickhardt, Hui K. Gan, Rodney J. Hicks, Sze Ting Lee, Pece Kocovski, Nancy Guo, Maggie Oh, Linda Mileshkin, Scott Williams, Declan Murphy, Kunthi Pathmaraj, Graeme J. O'Keefe, Sylvia J. Gong, John S. Pedersen, Fiona E. Scott, Michael P. Wheatcroft, Peter J. Hudson
Journal: Theranostics (2020)

Through protein engineering and a novel pegylation strategy, a diabody specific to tumor-associated glycoprotein 72 (TAG-72) (PEG-AVP0458) has been created to optimize pharmacokinetics and bioavailability to tumor.We report the preclinical and clinical translation of PEG-AVP0458 to a first-in-human clinical trial of a diabody.Methods: Clinical translation followed characterization of PEG-AVP0458 drug product and preclinical biodistribution and imaging assessments of Iodine-124 trace labeled PEG-AVP0458 ( 124 I-PEG-AVP0458).The primary study objective of the first-in-human study was the safety of a single protein dose of 1.0 or 10 mg/m 2 124 I-PEG-AVP0458 in patients with TAG-72 positive relapsed/ metastatic prostate or ovarian cancer.Secondary study objectives were evaluation of the biodistribution, tumor uptake, pharmacokinetics and immunogenicity.Patients were infused with a single-dose of 124 I labeled PEG-AVP0458 (3-5 mCi (111-185 MBq) for positron emission tomography (PET) imaging, performed sequentially over a one-week period.Safety, pharmacokinetics, biodistribution, and immunogenicity were assessed up to 28 days after infusion.Results: PEG-AVP0458 was radiolabeled with 124 I and shown to retain high TAG-72 affinity and excellent targeting of TAG-72 positive xenografts by biodistribution analysis and PET imaging.In the first-in-human trial, no adverse events or toxicity attributable to 124 I-PEG-AVP0458 were observed.Imaging was evaluable in 5 patients, with rapid and highly specific targeting of tumor and minimal normal organ uptake, leading to high tumor:blood ratios.Serum concentration values of 124 I-PEG-AVP0458 showed consistent values between patients, and there was no significant difference in T½α and T½β between dose levels with mean (± SD) results of T½α = 5.10 ± 4.58 hours, T½β = 46.19± 13.06 hours.Conclusions: These data demonstrates the safety and feasibility of using pegylated diabodies for selective tumor imaging and potential delivery of therapeutic payloads in cancer patients.
1022MO Clinical potential of adoptive cell therapy with tumour infiltrating lymphocytes therapy in combination with checkpoint inhibitors in non-melanoma patients
Authors: A.H. Kverneland, T.H. Borch, C. Chamberlain, C.L. Lorentzen, M. Nielsen, J.W. Kjeldsen, S.K. Moerk, M. Donia, I-M. Svane
Journal: Annals of Oncology (2020)
Immunotherapy during the acute SHIV infection of macaques confers long-term suppression of viremia
Authors: Yoshiaki Nishimura, Olivia K. Donau, Joana Dias, Sara Ferrando-Martinez, Eric Jesteadt, Reza Sadjadpour, Rajeev Gautam, Alicia Buckler-White, Romas Geleziunas, Richard A. Koup, Michel C. Nussenzweig, Malcolm A. Martin
Journal: The Journal of Experimental Medicine (2020)

We report that combination bNAb immunotherapy initiated on day 3 post-infection (PI) maintained durable CD8+ T cell–mediated suppression of SHIVAD8 viremia and preinoculation levels of CD4+ T cells in 9 of 13 treated monkeys during nearly 6 yr of observation, as assessed by successive CD8+ T cell–depletion experiments. In an extension of that study, two treatment interventions (bNAbs alone or cART plus bNAbs) beginning on week 2 PI were conducted and conferred controller status to 7 of 12 monkeys that was also dependent on control mediated by CD8+ cells. However, the median time to suppression of plasma viremia following intervention on week 2 was markedly delayed (85 wk) compared with combination bNAb immunotherapy initiated on day 3 (39 wk). In both cases, the principal correlate of virus control was the induction of CD8+ T cellular immunity.
Insights into disease mechanisms and potential therapeutics for C9orf72-related amyotrophic lateral sclerosis/frontotemporal dementia
Authors: Delia Gagliardi, Gianluca Costamagna, Michela Taiana, Luca Andreoli, Fabio Biella, Margherita Bersani, Nereo Bresolin, Giacomo Pietro Comi, Stefania Corti
Journal: Ageing Research Reviews (2020)
825P Olaparib maintenance therapy in routine clinical practice: Quality of life interim results of the non-interventional C-PATROL study in ovarian cancer patients in Germany
Authors: F. Marmé, F. Hilpert, M.K. Welslau, J.P. Grabowski, A. El-Balat, A. Hartkopf, R. Glowik, J. Sehouli
Journal: Annals of Oncology (2020)
80TiP Global phase III study of NUC-1031 plus cisplatin vs gemcitabine plus cisplatin for first-line treatment of patients with advanced biliary tract cancer (NuTide:121)
Authors: J.J. Knox, M.G. McNamara, L. Goyal, M. Doherty, D. Cosgrove, C. Springfeld, K. Sjoquist, J.O. Park, H. Verdaguer, C. Braconi, P. Ross, A. De Gramont, J.R. Zalcberg, D. Palmer, J.W. Valle
Journal: Annals of Oncology (2020)
542P Growth modulation index (GMI) of larotrectinib versus prior systemic treatments for TRK fusion cancer patients
Authors: A. Italiano, D.S. Hong, A. Briggs, J. Garcia-Foncillas, U.N. Lassen, G. Vassal, S. Kummar, C.M. van Tilburg, K. Keating, J.A. Reeves, M. Fellous, H. Nogai, T.W. Laetsch, A. Drilon
Journal: Annals of Oncology (2020)
962P Immunotherapeutic implications of mucin 1/16 expression in head and neck squamous cell carcinoma (HNSCC)
Authors: T. Rampias, N. Gavrielatou, O. Panagiota, I. Kotsantis, M. Anastasiou, A. Pantazopoulos, I. Chatzidakis, G. Kavourakis, C. Kontos, S. Golfinopoulos, A. Polyzos, E. Giotakis, A. Scorilas, P. Foukas, A. Psyrri
Journal: Annals of Oncology (2020)
1424MO Perioperative FLOT plus ramucirumab versus FLOT alone for resectable esophagogastric adenocarcinoma– Updated results and subgroup analyses of the randomized phase II/III trial RAMSES/FLOT7 of the German AIO and Italian GOIM
Authors: S-E. Al-Batran, R.D. Hofheinz, H. Schmalenberg, D. Strumberg, E. Goekkurt, S. Angermeier, T. Zander, J. Potenberg, H-G. Kopp, D. Pink, G.M. Siegler, M. Schenk, F. De Vita, E. Maiello, T. Gaiser, D. Sookthai, U.S. Bankstahl, C. Pauligk, T.O. Götze, N. Homann
Journal: Annals of Oncology (2020)
1233P Epidemiology of female lung cancer in tertiary level hospitals in Bangladesh
Authors: A.A.M. Khan, M.R. Islam, M.J. Alam, A.T.M.K. Hasan, K.A. Arman, M. Rahman, A. Hossain, M.N. Hossen, N. Khurshid
Journal: Annals of Oncology (2020)
EpCAM Signaling Promotes Tumor Progression and Protein Stability of PD-L1 through the EGFR Pathway
Authors: Hao-Nien Chen, Kang-Hao Liang, Jun-Kai Lai, Chun-Hsin Lan, Mei-Ying Liao, Shao-Hsi Hung, Yi-Ting Chuang, Kai-Chi Chen, William Wei-Fu Tsuei, Han-Chung Wu
Journal: Cancer Research (2020)

Abstract Although epithelial cell adhesion molecule (EpCAM) has previously been shown to promote tumor progression, the underlying mechanisms remain largely unknown. Here, we report that the EGF-like domain I within the extracellular domain of EpCAM (EpEX) binds EGFR, activating both AKT and MAPK signaling to inhibit forkhead transcription factor O3a (FOXO3a) function and stabilize PD-L1 protein, respectively. Treatment with the EpCAM neutralizing antibody, EpAb2-6, inhibited AKT and FOXO3a phosphorylation, increased FOXO3a nuclear translocation, and upregulated high temperature requirement A2 (HtrA2) expression to promote apoptosis while decreasing PD-L1 protein levels to enhance the cytotoxic activity of CD8+ T cells. In vivo, EpAb2-6 markedly extended survival in mouse metastasis and orthotopic models of human colorectal cancer. The combination of EpAb2-6 with atezolizumab, an anti-PD-L1 antibody, almost completely eliminated tumors. Moreover, the number of CD8+ T cells in combination-treated tumors was increased compared with atezolizumab alone. Our findings suggest a new combination strategy for cancer immunotherapy in patients with EpCAM-expressing tumors. Significance: This study shows that treatment with an EpCAM neutralizing antibody promotes apoptosis while decreasing PD-L1 protein to enhance cytotoxic activity of CD8+ T cells.
6MO Radiochemotherapy-induced changes in brain extracellular matrix are associated with tumour development in mouse recurrent glioblastoma model
Authors: A. Tsidulko, A. Suhovskih, M. Kolpakova, M. Politko, G. Kazanskaya, A. Volkov, O. Pashkovskaya, K. Kuper, O. Shevelev, E. Zavjalov, S. Aidagulova, E. Grigorieva
Journal: Annals of Oncology (2020)
615MO Phase Ib/II study of VERU-111, novel, oral tubulin inhibitor, in men with metastatic castration resistant prostate cancer (mCRPC) who failed an androgen blocking agent
Authors: M. Markowski, M.A. Eisenberger, R. Tutrone, C. Pieczonka, R.H. Getzenberg, D. Rodriguez, K.G. Barnette, M.S. Steiner, D.R. Saltzstein, E.S. Antonarakis
Journal: Annals of Oncology (2020)
452P A phase Ib dose escalation study of binimetinib plus mFOLFIRI in patients with metastatic RAS mutated colorectal cancer
Authors: V. Florou, C.D. Nevala-Plagemann, G.W. Gilcrease, J. Whisenant, K.E. Barber, I. Garrido-Laguna
Journal: Annals of Oncology (2020)
1513P Palliative care unit (PCU) at home: Impact on emergency room visits and the number of hospital admissions in cancer patients at the end of life in a rural environment
Authors: M.E. Iriarte Moncho, V. Palomar Abril, T. Soria Comes, M. Perez Bosch, A. Oltra-Ferrando
Journal: Annals of Oncology (2020)
1979MO Inhibition of fatty acid synthase (FASN) activity induces cytotoxicity on gefitinib- and osimertinib-resistant EGFR-mutated non-small cell lung cancer cells
Authors: E. Polonio, S. Palomeras, J. Bosch-Barrera, R. Porta-Balanya, J. Relat, J. Ciurana, S. Ruiz-Martínez, T. Puig
Journal: Annals of Oncology (2020)
1883P Fertility rates in Spanish young breast cancer patients (YBCP)
Authors: B. Cantos Sánchez de Ibarguen, B. Nunez Garcia, J. Sánchez Gonzalez, M. Blanco Clemente, R. Benlloch Rodríguez, E. Ramírez Medina, M.C. Vega Carrasco, C. Alfaro Autor, A.M. Morito Aguilar, G. Visedo, C. Traseira, J.R. Castelló Fortet, M. Provencio Pulla, M. Mendez Garcia
Journal: Annals of Oncology (2020)
LBA52 EMPOWER-Lung 1: Phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ≥50%
Authors: A. Sezer, S. Kilickap, M. Gümüş, I. Bondarenko, M. Özgüroğlu, M. Gogishvili, H.M. Turk, İ. Çiçin, D. Bentsion, O. Gladkov, P. Clingan, V. Sriuranpong, N. Rizvi, S. Li, S. Lee, G. Gullo, I. Lowy, P. Rietschel
Journal: Annals of Oncology (2020)
1130P BRAF and MEK inhibition in CDKN2A germline carriers and BRAF mutant melanoma
Authors: F. Spagnolo, B. Dalmasso, H. Helgadottir, V. Höiom, R. van Doorn, E. Kapiteijn, M. Potrony, S. Puig, P. Queirolo, P. Ghiorzo
Journal: Annals of Oncology (2020)
100P Evaluation of the circulating stromal biomarker VICM reflecting M1-like macrophage activity in metastatic melanoma patients treated with anti-PD-1 therapy
Authors: C. Jensen, D.P. Hurkmans, S.L. Koolen, J.G. Aerts, M.A. Karsdal, R.H. Mathijssen, N. Willumsen
Journal: Annals of Oncology (2020)
LBA58 ORR in patients receiving nivolumab plus radiotherapy in advanced non-small cell lung cancer: First results from the FORCE trial
Authors: F. Bozorgmehr, J.R. Fischer, M. Bischof, A. Atmaca, S. Wetzel, M. Faehling, D. Bottke, M. Wermke, E.G.C. Troost, G. Schmidtke-Schrezenmeier, T. Wiegel, V. van Laak, A. Stupavsky, W. Engel-Riedel, E. Ingenhoff, N. Reinmuth, J. Krisam, A. Stenzinger, M. Thomas, S. Rieken
Journal: Annals of Oncology (2020)
464P Pharmacokinetic analysis of NUC-3373 with and without leucovorin in patients with previously treated metastatic colorectal cancer (NuTide:302 study)
Authors: J. Graham, K.K. Ciombor, F. Aroldi, L.J. Rodgers, A. Coveler, J. Berlin, S. Blagden, J. Evans
Journal: Annals of Oncology (2020)
1337P The clincial utility of circulating free DNA (cfDNA) analysis in non-small cell lung cancer (NSCLC) in the United Kingdom
Authors: A. Greystoke, M. Carter, W. Griffiths, G. Laviste, A. Ortega-Franco, S. Rafee, N. Hannaway, A. Bridgewood, S. Hall, F.H. Blackhall
Journal: Annals of Oncology (2020)
1565P Clinical outcome after perioperative treatment on locally advanced and borderline pancreatic cancer: Experience of a single academic center
Authors: S. Roselló Keränen, C. Pizzo, M. Huerta, E. Muñoz, C. Alfaro-Cervello, R. Aliaga, A. Vera, E. Jordá, M. Garcés, D. Roda, N. Tarazona, D. Dorcaratto, J. Guijarro, V. Sánchiz, T. Fleitas, P. Lluch, I. Pascual, A. Ferrandez, A. Cervantes, L. Sabater
Journal: Annals of Oncology (2020)
Burnout among cancer professionals during COVID-19
Authors: Talha Khan Burki
Journal: The Lancet Oncology (2020)

Newly released results from two online surveys done by the European Society for Medical Oncology (ESMO) Resilience Task Force have outlined the extent to which the COVID-19 pandemic has affected burnout, job performance, and wellbeing in the global oncology workforce. The first survey was done from April 16 to May 3, 2020, and 1520 people from 101 countries participated. 38% of respondents stated that they had experienced feelings of burnout and 78% had felt increased concern for their personal safety since the onset of the pandemic.